Fig. 3From: Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)pCR rates by PD-L1 status and stromal TIL level. CI confidence interval, IC immune cell, pCR pathologic complete response, PD-L1 programmed death ligand 1, TCH + P docetaxel, carboplatin, and trastuzumab plus pertuzumab, T-DM1 + P trastuzumab emtansine plus pertuzumab, TIL tumor-infiltrating lymphocyteBack to article page